Study reveals comparable rates of freedom from biochemical failure at 5 years.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.
High rates of preserved sexual function with combination beam plus brachytherapy.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
At 5 years after seed implantation, 59% prostate cancer patients had preserved erectile function.
PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.
Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.
IMRT plus brachytherapy offers better PSA relapse-free and metastasis-free survival than high-dose IMRT alone.
In a study, the five-year biochemical failure-free survival rate was nearly 85%.
Researchers report good results using high-dose rather than low-dose interstitial brachytherapy.
By itself or combined with external beam radiation therapy, it offers excellent oncologic outcomes.
Modalities under investigation include laser ablation, hemiablative seed implantation, and results are promising.
Men with larger prostates are at higher risk for blood in urine.
Perineural invasion (PNI) and post-treatment PSA levels at 12 months strongly predict long-term PSA relapse-free survival (PRFS) after definitive brachytherapy seed implantation for prostate cancer (PCa), according to a study.
Brachytherapy appears to have significant advantages over EBRT in the treatment of men with low-risk and intermediate-risk prostate cancer.
Having performed more than 1,200 brachytherapy treatments, Michael F. Sarosdy, MD, is convinced that this is a far better choice than surgery.
PARIS—Cystoscopy prior to low dose rate (LDR) brachytherapy for prostate cancer is feasible and useful in identifying patients who require further investigation or intervention before seed implantation, researchers reported at the 27th Annual Congress of the European Association of Urology.
Noninvasive brachytherapy-like treatment may be a new option for men with prostate cancer.
SAN FRANCISCO—Brachytherapy may be a treatment option for patients with high-risk prostate cancer (HRPC), according to data presented here at the annual Genitourinary Cancers Symposium.
Combined external beam radiation therapy (EBRT) with a brachytherapy boost plus androgen deprivation therapy (ADT) is associated with excellent disease-free survival among men with intermediate-risk prostate cancer (PCa), researchers reported.
Investigators at Harvard Medical School in Boston developed models for predicting effective for predicting erectile function two years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. John Schieszer has the story in today's Medical Minute.
The lowest rate of these complications was observed among patients treated with brachytherapy alone.
Brachytherapy offers excellent oncologic outcomes and is associated with a low rate of adverse events, data show.
Brachytherapy may provide an effective alternative treatment for younger men who are reluctant to undergo surgery for favorable risk prostate cancer, according to Canadian researchers.
Adding androgen deprivation therapy (ADT) to brachytherapy for localized prostate cancer may increase the risk of death among men aged 73 years and older, data suggest.
Bladder-sparing protocol involving brachytherapy and EBRT shows promise in bladder cancer patients.
A triple combination of brachytherapy, external beam radiotherapy (EBRT), and hormonal therapy is associated with favorable outcomes in men with high-grade prostate cancer and should be considered a viable treatment option in these patients, a study showed.
ORLANDO—Neoadjuvant androgen suppression therapy (AST) prior to brachytherapy may be associated with an increased risk of all-cause mortality in men with favorable-risk prostate cancer who have pre-existing cardiovascular disease (CVD).
Bulbomembranous (BM) urethral strictures are the most common grade 2 or higher urinary toxicity following high dose rate brachytherapy (HDRB), according to Australian investigators.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)